Skip to main content
Healthcare

STAT+: FDA rejects lung cancer treatment ivonescimab from Summit Therapeutics

STAT+: FDA rejects lung cancer treatment ivonescimab from Summit Therapeutics

Feed excerpt — reported by STAT News

The FDA has rejected ivonescimab, a treatment for a type of lung cancer developed by U.S. biotech Summit Therapeutics and the Chinese drugmaker Akeso. 

MAP records observable characteristics of the original article (publisher, author, date, references, framing cues). MAP does not verify the article’s claims or score it. Read the full original story at STAT News →

Original Source

This article was syndicated from STAT News. All rights remain with the original publisher.